SyneuRx International

Summary

SyneuRx International (Taiwan) Corp., a clinical-stage biotech company, develops drugs for the treatment of unmet medical needs in central nervous system disorders in Taiwan. Its pipeline includes Pentarlandir, which is in Phase II clinical trials for COVID-19; Airnecflu that is in Phase I clinical trials for COVID-19; NaBen, which is in Phase III clinical trials for adult schizophrenia, as well as in Phase II clinical trials adolescent schizophrenia; ClozaBen that is in Phase II clinical trials for refractory schizophrenia; NaBen, which is in Phase II clinical trials for early dementia; Tannquilynne that is in Phase II clinical trials for dementia and psychosis; Synapsinae, which is in Phase II clinical trials for early dementia and psychosis; and Synxyrin that is in Phase II clinical trials for early TRD and suicidality. SyneuRx International (Taiwan) Corp. was founded in 2013 and is based in New Taipei City, Taiwan.